A discussion of the Food and Drug Administration's attempts to regulate forms of scientific and commercial speech about pharmaceuticals that should merit First Amendment protection. This examination includes the effects of regulation on the marketplace, consumers, and the First Amendment. With an introduction by veteran journalist John Seigenthaler, chairman of the Freedom Forum First Amendment Center. Authors include Washington attorneys James Johnstone and Arthur Levine; Richard Kaplar of The Media Institute; marketing professor John Calfee; and economics professor Paul H. Rubin.
